



# 1Q-26 Quarterly Results

# Cautionary Note

- This presentation contains, and the officers of Teladoc Health, Inc. (the “Company” or “Teladoc Health”) may make, “forward-looking” statements that are based on management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of the Company’s business plan and strategies. These statements often include words such as “outlook,” “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” and other similar expressions.
- Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements are based on certain assumptions that Teladoc Health has made in light of the Company’s experience in the industry and its perception of historical trends, current conditions, expected future developments, and other factors the Company believes are appropriate under the circumstances as of the date hereof. Such risks and other factors that may impact management’s beliefs and assumptions are more particularly described in Teladoc Health’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including under “Item 1A.—Risk Factors” in the Company’s Annual Report on Form 10-K, and under similar headings in the Company’s subsequently filed Quarterly Reports on Form 10-Q, and could cause the Company’s results to differ materially from those expressed in forward-looking statements. As a result, Teladoc Health cannot guarantee future results, outcomes, levels of activity, performance, developments, or achievements, and there can be no assurance that the Company’s expectations, intentions, anticipations, beliefs, or projections will result or be achieved or accomplished. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, Teladoc Health assumes no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
- This presentation may contain estimates and other statistical data made by independent parties and by Teladoc Health relating to market size and growth and other data about the Company’s industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
- This presentation may include certain non-GAAP financial measures as defined by SEC rules. Teladoc Health believes that the presentation of such non-GAAP financial measures enhances an investor's understanding of the Company’s financial performance. Teladoc Health uses certain non-GAAP financial measures for business planning purposes and in measuring the Company’s performance relative to that of its competitors. For additional information regarding these non-GAAP financial measures, including reconciliations to the most directly comparable financial measure calculated according to GAAP, refer the appendix to this presentation. Teladoc Health has not provided a full line-item reconciliation for net loss to adjusted EBITDA outlook because the Company does not provide outlook on the individual reconciling items between net loss and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as impairments, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.

# Key Financial Data

**1Q-26 Revenue of \$614M, (2)% y/y**

**1Q-26 Net loss per share of \$(0.36)<sup>(1)</sup>**

**1Q-26 Adj. EBITDA<sup>(2)</sup> of \$58.2M, 0% y/y**

**FY-26 Revenue outlook range of \$2,481M to \$2,576M**

- 2Q-26 Revenue outlook range of \$597M to \$626M

**FY-26 Net loss per share outlook range of \$(1.05) to \$(0.75)**

- 2Q-26 Net loss per share outlook range of \$(0.30) to \$(0.20)

**FY-26 Adj. EBITDA outlook range of \$267M to \$306M**


- 2Q-26 Adj. EBITDA outlook range of \$55M to \$67M

(1) Net loss per share includes restructuring cost of \$0.07 per share pre-tax, stock-based compensation expense of \$0.08 per share pre-tax and amortization of intangibles of \$0.50 per share pre-tax.


(2) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation.

# 1Q-26 Consolidated Revenue & Adj. EBITDA

Revenue (\$ millions)




Adj. EBITDA (\$ millions)<sup>(1)</sup>




(1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation.

# Quarterly Segment<sup>(1)</sup> Results


**Integrated Care Segment Revenue (\$ millions)**




**BetterHelp Segment Revenue (\$ millions)**



**Integrated Care Segment Adjusted EBITDA (\$ millions)**




**BetterHelp Segment Adjusted EBITDA (\$ millions)**




(1) The Company has two segments: Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis, which are predominantly marketed and sold on a direct-to-consumer basis.

# 1Q-26 Revenue: U.S. & International

**U.S. Revenue (\$ millions)**




**International Revenue (\$ millions)**




# Quarterly Key Operating Metrics


## U.S. Integrated Care Members<sup>(1)</sup> (millions)




## BetterHelp Paying Users<sup>(2)</sup> (thousands)



## Average Monthly Revenue per U.S. Integrated Care Member<sup>(3)</sup>




## Chronic Care Program Enrollment<sup>(4)</sup> (thousands)



1. U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to Teladoc Health's suite of integrated care services in the U.S. at the end of the applicable period.
2. BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy and psychiatry services during the applicable period, including both those who pay directly out-of-pocket and those who utilize their insurance coverage.
3. Average monthly revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 1) during the applicable period.
4. Chronic Care Program Enrollment represents the total number of enrollees across Teladoc Health's suite of chronic care programs at the end of the applicable period.

# Quarterly Adjusted EBITDA & Adjusted EBITDA Margin

## Adj. EBITDA<sup>(1)</sup> (\$ millions) & Adj. EBITDA Margin



(1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation.

# Balance Sheet and Cash Flow Highlights

- **Cash and Cash Equivalents**  
(as of March 31, 2026): **\$751M**
- **Convertible Senior Notes**  
(as of March 31, 2026): **\$996M**
- **Operating Cash Flow**  
(1Q-26): **\$10M**
- **Free Cash Flow** <sup>(1)</sup>  
(1Q-26): **\$(26)M**

(1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation.



## Outlook: 2Q-26 and FY-26

	<b>2Q-26</b>	<b>Y/Y % Growth</b>	<b>FY-26</b>	<b>Y/Y % Growth</b>
<b>Revenue (\$M)</b>	<b>\$597 to \$626</b>	<b>(6)% to (1)%</b>	<b>\$2,481 to \$2,576</b>	<b>(2)% to 2%</b>
<b>Net loss per share</b>	<b>\$(0.30) to \$(0.20)</b>	<b>NM</b>	<b>\$(1.05) to \$(0.75)</b>	<b>NM</b>
<b>Adj. EBITDA (\$M)</b>	<b>\$55 to \$67</b>	<b>(20)% to (3)%</b>	<b>\$267 to \$306</b>	<b>(5)% to 9%</b>
<b>US Integrated Care Members (M)</b>	<b>98.5 to 100</b>	<b>(4)% to (2)%</b>	<b>97 to 100</b>	<b>(5)% to (2)%</b>

NM = not meaningful

# Appendix

# Reconciliation of GAAP Net Loss to Adjusted EBITDA

	1Q-25	2Q-25	3Q-25	4Q-25	1Q-26
Net loss	\$(93,012)	\$(32,660)	\$(49,507)	\$(25,143)	\$(63,837)
Add:					
Provision for income taxes	(18,255)	(7,763)	(715)	(8,475)	2,995
Other expense (income), net	(2,435)	(8,371)	815	(378)	196
Interest expense	5,765	4,473	4,526	4,950	5,368
Interest income	(12,674)	(10,064)	(7,081)	(6,951)	(6,490)
Depreciation of property and equipment	3,564	4,338	2,612	2,800	2,461
Amortization of intangible assets	84,304	88,664	85,757	92,039	89,826
Restructuring costs	4,347	5,692	1,950	6,796	11,975
Acquisition, integration, and transformation costs	2,188	2,658	1,931	2,233	1,064
Goodwill impairment	59,138	—	12,625	—	—
Stock-based compensation	25,163	22,344	16,996	15,911	14,611
<b>Adjusted EBITDA</b>	<b>\$58,093</b>	<b>\$69,311</b>	<b>\$69,909</b>	<b>\$83,782</b>	<b>\$58,169</b>

(in 000s)

# Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow

	1Q-26
Net cash provided by operating activities	\$9,516
Capital expenditures	(1,660)
Capitalized software development costs	(34,162)
Capex	(35,822)
Free Cash Flow	<u><u>\$(26,306)</u></u>

(in 000s)

**Teladoc**<sup>®</sup>  
HEALTH